New drug shows promise against tough blood cancers in early trial
NCT ID NCT05526313
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This early-stage study tested a new drug called Purinostat Mesylate in 29 people with blood cancers like diffuse large B-cell lymphoma that had returned or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see how the body processes it. Results from animal studies suggested the drug could shrink tumors with manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.